10 th World Congress on ADHD 8 – 11 May 2025 Prague Congress Centre Czech Republic
FINAL PROGRAMME www.adhd-congress.org
TABLE OF CONTENTS
Page
Welcome Address
3
CONGRESS APP Get the 10 th World Congress on ADHD app for your smartphone now and experience the congress at your fingertips! Quickly find your way through the most up-to-date congress schedule. Stop carrying around piles of paper. Just take the congress with you, wherever and whenever you want! The App is free of charge and provides iPhone / iPad and Android users at the 10 th World Congress on ADHD with on-the-go access to the congress' most exciting interactive features.
Organization
4
Committees
5
WORLD FEDERATION
World Federation of ADHD
6
Overview of Meeting Rooms
7
Format Descriptions
10
Programme Overview
11
CME Credits
14
Scientific Programme Thursday, 8 May 2025
15 18 30 43
Friday, 9 May 2025
Further information is given at www.adhd-congress.org/app
Saturday, 10 May 2025 Sunday, 11 May 2025
Patient's Day
45
General Information
47
Late Breaking Insights
51
Acknowledgements
52
List of Exhibitors
52
Exhibition Map
53
List of Chairpersons and Presenters
54
For your Notes
64
2
WELCOME ADDRESS
Dear Colleagues,
It is with great pleasure that we welcome you to the World Congress on ADHD in Prague, Czech Republic. We are honored to have the opportunity to bring together clinicians and researchers from around the world to discuss the latest developments in the field of ADHD. Our federation is dedicated to supporting and promoting clinical studies, scientific projects, and training programs related to ADHD and related disorders. By bringing together experts from a variety of backgrounds and disciplines, we can enhance the exchange of information and advance our understanding of these conditions. This congress provides an excellent opportunity for us to share our knowledge and expertise, as well as to learn from each other. We hope that you will take advantage of the many opportunities to network and collaborate with your colleagues from around the world.
Thank you for your participation and support, and we look forward to a productive and inspiring congress.
Sincerely yours,
Stephen Faraone Congress President President WFADHD
Manfred Gerlach Chair Scientific Programme Committee
Luis Augusto Rohde Chair Schientific Programme Committee
Maggie Sibley Chair Scientific Programme Committee
Anita Thapar Chair Scientific Programme Committee
3
ORGANIZATION
CONGRESS PRESIDENT Stephen Faraone SUNY Upstate Medical University Syracuse, NY, USA SCIENTIFIC PROGRAMME COMMITTEE Manfred Gerlach University of Würzburg Würzburg, Germany Luis Augusto Rohde Federal University of Rio Grande del Sul Porto Allegre, Brazil
CONGRESS VENUE Prague Congress Centre 5. kvetna 65, Entrance 4 140 21 Praha 4, Czech Republic
ORGANIZER World Federation of ADHD
Global Head Office Zum Ehrenhain 34
22885 Barsbüttel, Germany Phone: +49 – 40 – 670 88 20 Email: adhd@cpo-hanser.de
CONGRESS AND EXHIBITION OFFICE
Maggie Sibley University of Washington Seattle, Washington, USA Anita Thapar Cardiff University Cardiff, United Kingdom
Hanser & Co GmbH Zum Ehrenhain 34
22885 Barsbüttel, Germany Phone: +49 – 30 – 300669-0 Email: adhd2025@cpo-hanser.de
Please visit the Poster Exhibition . at Congress Hall Foyer 2B (2nd Floor).
4
COMMITTEES
SCIENTIFIC PROGRAMME COMMITTEE Chairs: M. Gerlach, Germany L. A. Rohde, Brazil M. Sibley, USA A. Thapar, United Kingdom L. Adler, USA H. F. Aljoudi, Saudi Arabia D. Almagor, Canada K. Antshel, USA P. Asherson, United Kingdom T. Banaschewski, Germany M. Bellgrove, Australia J. Boavida, Portugal S. Bölte, Sweden J. Buitelaar, The Netherlands F. X. Castellanos, USA A. Childress, USA D. Coghill, Australia S. Cortese, United Kingdom J. Crosbie, Canada M. Döpfner, Germany A. E. Doyle, USA D. Fair, USA S. Faraone, USA B. Franke, The Netherlands S. Shur-Fen Gau, Taiwan M. Gignac, Canada D. Goodman, USA P. Hoekstra, The Netherlands X. Ke, People's Republic of China B. Kim, Republic of Korea S. Kollins, USA S. Kooij, The Netherlands K.-P. Lesch, Germany I. Manor, Israel G. Mattingly, USA P. Mattos, Brazil C. Middeldorp, The Netherlands A. Miranda, Spain T. Miyajima, Japan B. Molina, USA Z. Morillo de Nieto, Dominican Republic A. Mykletun, Norway J. Newcorn, USA J. Nigg, USA A. Philipsen, Germany
J. A. Ramos-Quiroga, Spain A. Reif, Germany P. Riederer, Germany M. Romanos, Germany K. Rubia, United Kingdom J. Rucklidge, New Zealand R. Schachar, Canada P. Shaw, USA T. Silk, Australia
D. Silva, Australia M. Solanto, USA E. Sonuga-Barke, United Kingdom
C. Soutullo, Spain C. B. Surman, USA M. Stein, USA J. Swanson, USA J. Thome, Germany O. Tucha, Germany
A. Venter, South Africa S. Walitza, Switzerland L.-J. Wang, People's Republic of China
J. Waxmonsky, USA M. Weiss, Canada T. Wilens, USA
L. Yang, People's Republic of China Y. Zheng, People's Republic of China
LOCAL ORGANIZING COMMITTEE Chair: Michal Goetz, Czech Republic
Pavel Mohr, Czech Republic Jan Č ermák, Czech Republic Radek Ptá č ek, Czech Republic, († 1 September 2024)
Pavel Theiner, Czech Republic David Havelka, Czech Republic Hana Papežová, Czech Republic Ladislava Pejzlová, Czech Republic
POSTER PRIZE COMMITTEE Chair: Oliver Tucha, Germany
Edna Grünblatt, Switzerland Pavel Mohr, Czech Republic Pavel Theiner, Czech Republic Li Yang, People's Republic of China
G. Polanczyk, Brazil D. Quinn, Canada
5
WORLD FEDERATION OF ADHD
WORLD FEDERATION OF ADHD
In August 2008, the World Federation of ADHD (Attention-Deficit/Hyperactivity Disorder) and allied disorders was foun- ded in Zurich, Switzerland. Andreas Warnke, former Director of the Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy at the University of Würzburg, Germany, was officially nominated the first president of this non-profit organisation. The purpose of the World Federation of ADHD and allied disorders is to support and promote clinical studies, scientific projects and training programmes in the field of ADHD and related disorders worldwide, as well as to enhance the ex- change of information between scientists, physicians, health experts, ADHD lay organisations and the public. In addition to achieving these goals, every second year, the World Federation of ADHD holds the World Congress which attracts numerous delegates from all over the world who want to learn about the latest research findings and perspec- tives on ADHD.
World Federation of ADHD, Global Head Office CPO HANSER SERVICE Zum Ehrenhain 34 22885 Barsbüttel, Germany
Phone: +49 – 40 – 670 88 20 Email: adhd@cpo-hanser.de
GENERAL ASSEMBLY – for members only 8 May 2025 | 14:00–14:45 | Club A (1 st Floor)
BECOME A MEMBER NOW!
WORLD FEDERATION OF ADHD
Advantages e Substantially reduced registration fees for World Congress of ADHD Congresses e Networking with colleagues worldwide e Reasonable annual membership fee EUR 50
The only global federation focused on ADHD and allied disorders e Education about ADHD
e Advocacy for patients and their families by teaching clinicians, researchers and other ADHD stakeholders e Promoting research into causes, prevention and treatment of ADHD e Promoting public policy that will affect the care of patients favourably and lay organisations
e e Visit us at www.adhd-federation.org
6
OVERVIEW OF MEETING ROOMS PRAGUE CONGRESS CENTRE
GROUND FLOOR
7
OVERVIEW OF MEETING ROOMS PRAGUE CONGRESS CENTRE
1 ST FLOOR
8
OVERVIEW OF MEETING ROOMS PRAGUE CONGRESS CENTRE
2 ND FLOOR
Art Exhibition
9
FORMAT DESCRIPTIONS
PLENARY SESSIONS (PL) Duration: 90/120 min.
EDUCATIONAL SEMINARS (ES) Duration: 60 min.
These sessions provide a broad overview of the latest clinical and basic science research findings and state-of-the-art infor- mation in the field of ADHD. Each session is composed of three to four 30-minute lectures presented by international well-known experts in the field of ADHD. After the talks there will be no discussion.
Educational Seminars are designed to be informal and inter- active and provide up-to-date information on a single topic. The courses highlight both the clinical and basic science of topics relevant to ADHD. These seminars provide ample time for questions and a discussion period at the conclusion of the presentations. Attendance is limited to allow participants greater opportunities for active participation. Therefore, it is recommendable to book the ticket together with the congress registration online or to check ticket availability on-site at the registration counter. Tickets will be handled on a 'first-come, first-served' basis. Registration fee per session: EUR 60. Only valid in combination with the congress registration fee.
HOT TOPIC SYMPOSIA (HT) Duration: 90 min.
Hot Topic Symposia feature comprehensive reviews of the most recent research results as well as practical issues in the field of ADHD. Each 90-minute symposium, presented by internationally recognized clinicians and neuroscientists, con- tains a theme of topical interest and is composed of three or four lectures, with a maximum of 20 minutes. After the talks there will be short discussions.
MEET-THE-EXPERT SESSIONS (ME) Duration: 60 min.
Meet-the-Expert Sessions will allow participants to meet in small groups with outstanding researchers and clinicians in the field of ADHD. The format is designed to facilitate informal discussions, allowing participants to present their questions and gain new perspectives. The sessions are open to all parti- cipants but tickets are handled strictly on a 'first-come, first- served' basis. Registration fee per session: EUR 60. Only valid in combination with the congress registration fee.
PRO-CON-DEBATE (PC) Duration: 90 min.
In this debate a current controversial issue in the field of ADHD is introduced and discussed. This session is designed to involve all attendees of the congress. One moderator and two dis- cussants (pro and con) will raise interactive and lively debates. EARLY CAREER SCIENTIST AWARD SYMPOSIUM (ECSAS) Duration: 90 min. There are two symposia dedicated to Early Career Scientists selected from submitted abstracts by the Scientific Program Committee, each comprising four 20-minute lectures and chaired by recognized experts for the featured topic. Applicants must be 35 years old or younger at the time of submission. One symposium is held in honour of Joseph Sergeant. The second is held in honour of Joseph Biederman (†).
GRAND ROUND (GR) Duration: 90 min.
This is an interactive session moderated by a well-known ex- pert, where a topic of interest relevant to ADHD is presented. The topic presented will represent a challenge of broad interest to the audience and aim to nurture discussions.
GUIDED POSTER TOURS (P) Duration: 120 min.
LATE BREAKING NEWS (LN) Duration: 30 min.
The Guided Poster Tours gather the accepted posters submit- ted and give each delegate an opportunity to view their colleagues´ posters on the most current findings in the field of ADHD. Posters will be grouped by topics for the conveni- ence of those attending the sessions. The tours are chaired by leaders in various fields of ADHD. During the tours, the first author of the abstract will have 3 minutes to explain the work and then answers questions for 3 minutes. The posters will be displayed in the poster exhibition hall for the duration of one presentation day.
During these sessions speakers discuss most recently published papers on ADHD, which they consider clinically most important and cutting-edge in their discipline. These sessions are a great way to get up-to-speed with the latest development in the field of ADHD.
10
PROGRAMME OVERVIEW Thursday, 8 May 2025
Room
Congress Hall
Panorama Hall
North Hall
South Hall 2A
South Hall 2B
Congress Hall Foyer 2A
Congress Hall Foyer 2C
Club A
Time
14.00
GA-01 General Assembly of WFADHD
14.30
15.00
HT-01 Should I need to worry about cardiovascular risks outcomes in my patients with ADHD treated with psycho- stimulants?
HT-02 The lancet psychiatry series on ADHD
HT-03 ADHD and global crises
HT-04 Navigating ADHD in the perinatal period
HT-05 Joint Symposium of the Affiliated Societies of the World Federation of ADHD
HT-06 Inflammation and ADHD: The neurobiological mechanisms and clinical associa- tions
15.30
16.00
16.30
Exhibition Area COFFEE BREAK Exhibition Area
LN-01 see page 16
17.00
HT-07 Clinical dilem- mas in treating patients with medication
HT-08 Multi-component cognitive behav- ioural therapy for ADHD: From preschool to adulthood
HT-09 ADHD: Why are we waiting and what are you go- ing to do about this?
HT-10 Hazard environ- mental exposure and the develop- ment of ADHD: Evidence from large population study
HT-11 Neurodiversity approach: Evi- dence for posi- tive and strength focused aspects in ADHD
HT-12 ADHD in college- aged adults
17.30
18.00
18.30
19.00
19.30
OC-01 Opening Ceremony (Congress Hall)
20.00
20.30
SP-01 Networking Reception (Congress Hall Foyer 2C)
21.00
21.30
Registration 08:00 – 20:00 (Ground Floor)
Technical Exhibition 14:30 – 21:30 (Congress Hall Foyer 2A + 2C)
Session types in alphabetical order
ECSAS
Early Career Scientist Award Symposium
ME
Meet-the-Expert Session
ES
Educational Seminar
OP
Opening Ceremony
GR
Grand Round
P
Guided Poster Tour
HT
Hot Topic Symposium
PC
Pro-Con-Debate
LB
Late Breaking Insights (Industry Session)
PS
Plenary Session
LN
Late Breaking News
SP
Special Session
e Registration fee for Educational Seminars and Meet-the-Expert Session: EUR 60 per session. Only valid in combination with the congress registration fee.
11
PROGRAMME OVERVIEW Friday, 9 May 2025
Congress Hall Foyer 2A
Congress Hall Foyer 2B
Room
Congress Hall
Panorama Hall
North Hall
South Hall 2A
South Hall 2B
Club A Club B
Time
08.30
PL-01 Translating ADHD research to clinical world
09.00
09.30
10.00
Exhibition Area COFFEE BREAK Exhibition Area
LB-01 see page 51
10.30
PL-02 ADHD and trauma across the lifespan
11.00
11.30
12.00
Exhibition Area COFFEE BREAK Exhibition Area
LB-02 see page 51
12.30
13.00
13.30
P Guided Poster Tours (Congress Hall Foyer 2B)
14.00
14.30
15.00
HT-13 Female
HT-14 ADHD coach- ing on the rise: Understanding coaches and their role in support
HT-15 ADHD and substance use disorders
HT-16 Assessment and manage- ment of ADHD
HT-17 Novel bio-
ECSAS-01 Early Career Scientist Symposium dedicated to Joseph Sergeant
15.30
ADHD and the impact of hormones on mood and health across the lifespan
logical targets and treatment approaches in ADHD
in Autism Spectrum Disorders
16.00
16.30
ME-04 Assessment and manage- ment of sleep challenges in ADHD
ME-01 Clinical tips in assessing and treating child- ren with ADHD
ME-02 How to treat refractory ADHD?
ES-01 ADHD in older adults
ES-02 Doctor-patient communica- tion from the perspective …
ME-03 The Challenge of the Neuro- diversity Movement
17.00
17.30
Registration 08:00 – 17:00 (Ground Floor)
Technical Exhibition 09:00 – 17:00 (Congress Hall Foyer 2A + 2C)
Poster Exhibition 09:00 – 17:00 (Congress Hall Foyer 2B)
12
PROGRAMME OVERVIEW Saturday, 10 May 2025
Congress Hall Foyer 2A
Congress Hall Foyer 2B
Room
Congress Hall
North Hall
South Hall 2A
South Hall 2B
Club A
Club B
Time
08.30
PL-03 Are ADHD medication safe? New data of long-term studies
09.00
09.30
10.00
Exhibition Area COFFEE BREAK Exhibition Area
LB-03 see page 51
10.30
PC-01 Does cognitive behavioral thera- py adversely en- courage patients with ADHD to mask their true selves?
11.00
11.30
12.00
Exhibition Area COFFEE BREAK Exhibition Area
LB-04 see page 51
12.30
13.00
13.30
P Guided Poster Tours (Congress Hall Foyer 2B)
14.00
14.30
15.00
HT-18 Two treatments better than one? Investigat- ing combined treatments for childhood ADHD
HT-19 Joint Symposium of the Affiliated Societies of the World Federa- tion of ADHD
HT-20 Is physical
HT-21 Clinical perspec- tives on ADHD and antisocial behavior: Risks, strategies, and outcomes
HT-22 Driving infrac- tions and crashes in adults with ADHD vs. control subjects
ECSAS-02 Early Career Scientist Symposium dedicated to Joseph Biederman
15.30
activity a treat- ment option for ADHD?
16.00
16.30
ME-05 Clinical pearls in managing stimulant side effects
ES-03 The advantages and limitations of drug holidays
ME-06 Psychoeducation, cognitive-behav- ioural treatment and new …
ME-07 New perspectives and techniques in the intervention of ADHD
ES-04 Assessment strategies of ADHD in adults
17.00
17.30
Registration 08:00 – 17:00 (Ground Floor)
Technical Exhibition 09:00 – 17:00 (Congress Hall Foyer 2A + 2C)
Poster Exhibition 09:00 – 17:00 (Congress Hall Foyer 2B)
13
PROGRAMME OVERVIEW Sunday, 11 May 2025
Room
Congress Hall
Congress Hall Foyer 2A
Time
08.30
09.00
GR-01 Do I Have ADHD? Exploring self-referral, trajectories and potential individualization of treatment
09.30
10.00
Early Career Scientist Awards & Best Poster Prizes
10.30
COFFEE BREAK Exhibition Area PL-04 Adult ADHD: Essential insights every health professional must know
LN-02 see page 43
11.00
11.30
12.00
12.30
Registration 08:30 – 12:30 (Ground Floor)
CME CREDITS The 10 th World Congress on ADHD, Prague, 8 – 11 May 2025 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME ® ) with 17,5 European CME credits (ECMEC ® s) .
Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.
Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME ® credits to an equivalent number of AMA PRA Category 1 Credits TM . Information on the process to convert EACCME ® credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-international-activities . Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME ® for ECMEC ® s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada. EACCME ® credits Each participant can only receive the number of credits he /she is entitled to according to his /her actual participation at the event once he/she has completed the feedback form.
Breakdown of ECMEC ® s per day: 8 May 2025 e 3,0 credits 9 May 2025 e 5,5 credits 10 May 2025 e 5,5 credits 11 May 2025 e 3,5 credits
14
SCIENTIFIC PROGRAMME Thursday, 8 May 2025
GA-01 General Assembly 14:00 – 14:45
HT-03 Hot Topic Session 15:00 – 16:30
Club A
North Hall
General Assembly of WFADHD Access for members of the WFADHD and nominated representatives of affiliated associations only.
ADHD and global crises Chairs: Thomas Müller, Switzerland Jeffrey Newcorn, USA 001
Prenatal exposure to a natural disaster and early development of psychiatric disorders during the preschool years: Stress in preg- nancy study Jeffrey Newcorn, USA The effect of COVID-19 Pandemic on ADHD Mark Bellgrove, Australia
HT-01 Hot Topic Session 15:00 – 16:30
Congress Hall Should I need to worry about cardiovascular risks out- comes in my patients with ADHD treated with psy- chostimulants? Chairs: Samuele Cortese, United Kingdom Jonna Kuntsi, United Kingdom 001 ADHD medications and long-term risk of cardiovascular diseases Zheng Chang, Sweden 002 Long-term cardiovascular safety of methyl- phenidate in children and adolescents with ADHD: 2-year outcomes of the ADHD Drugs Use Chronic Effects (ADDUCE) study Ian Chi Kei Wong, Hong Kong
002
003
ADHD and climate change Thomas Müller, Switzerland
HT-04 Hot Topic Session 15:00 – 16:30
South Hall 2A
Navigating ADHD in the perinatal period Chairs: Kathrine Bang Madsen, Denmark Lotta Borg Skoglund, Sweden 001
It’s all in your head: Hormonal changes across the female reproductive life Helena Kopp Kallner, Sweden M aternal mental health in the perinatal period: Challenges and strategies for women with ADHD Lotta Borg Skoglund, Sweden Short and long-term outcomes for infants exposed to ADHD medications in utero Kathrine Bang Madsen, Denmark ADHD medication use during pregnancy: Balancing benefits and risks Jacqueline Mallory Cohen, Norway
003
ADHD Remote Technology study of cardio- metabolic risk factors and medication adher- ence (ART-CARMA): A multi-centre prospective cohort study Jonna Kuntsi, United Kingdom Comparative cardiovascular side effects of medications for ADHD in children, adolescents and adults: Systematic review and network meta-analysis Samuele Cortese, United Kingdom
002
004
003
004
HT-02 Hot Topic Session 15:00 – 16:30
Panorama Hall
HT-05 Hot Topic Session 15:00 – 16:30
The lancet psychiatry series on ADHD Chairs: David Coghill, Australia Luis Augusto Rohde, Brazil 001
South Hall 2B Joint Symposium of the Affiliated Societies of the World Federation of ADHD Chairs: Sandra Kooij, The Netherlands Arnstein Mykletun, Norway 001 (Not) sleeping and suffering: the interplay bet- ween AD(H)D, sleep disorders and psychiatric comorbidity Dora Wynchank, The Netherlands
C urrent evidence and gaps on global ADHD and treatment epidemiology Adrienne Chan, United Kingdom What are the real-world long-term impacts of ADHD and its treatment: Clinical, societal, economic and political implications Patrick Ip, Hong Kong Barriers and facilitators for improving equity of access to ADHD care Luis Augusto Rohde, Brazil
002
003
002
The effect of light therapy on ADHD symptoms in adults Sandra Kooij, The Netherlands
004
Psychoeducation and advocacy David Coghill, Australia
15
SCIENTIFIC PROGRAMME Thursday, 8 May 2025
003
Is getting an ADHD-diagnosis harmful or beneficial for children in the grey zone for the diagnosis Arnstein Mykletun, Norway The usual suspects and beyond – decontex- tualization as explanation for the suboptimal uptake of parenting interventions Tycho Dekkers, The Netherlands
HT-08 Hot Topic Session 17:00 – 18:30
Panorama Hall Multi-component cognitive behavioural therapy for ADHD: From preschool to adulthood Chairs: Margaret Sibley, USA Jinsong Zhang, People’s Republic of China 001 New forest parenting program for preschool children with ADHD in China Jinsong Zhang, People’s Republic of China 002 E xecutive skills training (multi-component cog- nitive behavioral therapy to both children and parents) for 6-12 children with ADHD: Face- to-face and on-line, first dosage and second dose Ying Qian, People’s Republic of China
004
HT-06 Hot Topic Session 15:00 – 16:30
Club A Inflammation and ADHD: The neurobiological mecha- nisms and clinical associations Chairs: Iris Manor, Israel Timothy Nielson, Australia 001 A ssociation of maternal autoimmune disease with ADHD in children Timothy Nielsen, USA 002 Evaluation of maternal inflammation as a marker of future offspring ADHD symptoms: A prospective investigation Iris Manor, Israel
003
Cognitive-behavioral treatments for adoles- cents with ADHD: A systematic review of the literature Margaret Sibley, USA Cognitive-behavioral treatments for adults with ADHD: Systematic review with meta- analysis Carlos López Pinar, Spain
004
003
Inflammation: An underlying factor linking ADHD and Asthma Symptoms? Douglas Teixeira Leffa, USA
HT-09 Hot Topic Session 17:00 – 18:30
North Hall ADHD: Why are we waiting and what are you going to do about this? Chairs: Sven Bölte, Sweden Anita Thapar, United Kingdom 001 Experiences of being on a waiting list and
LN-01 Late Breaking News 16:30 – 17:00 Late Breaking Stage (2 nd Floor) Exploring chronic emotional burden as a pathway to depression and anxiety in adolescents with ADHD: A focus beyond emotional control deficits Introducer: Edmund Sonuga-Barke, United Kingdom Interviewers: A rthur Caye, Brazil Katherine Ellison, USA Congress Hall Clinical dilemmas in treating patients with medication Chairs: David Coghill, Australia Jeffrey Newcorn, USA 001 What makes and how to approach ADHD complex cases? Jeffrey Newcorn, USA 002 Are drug holidays a valid strategy in ADHD treatment David Coghill, Australia 003 HT-07 Hot Topic Session 17:00 – 18:30 Treating ADHD refractory cases Samuele Cortese, United Kingdom
ideas on what might help Ceri Reed, United Kingdom
002
Waiting for Godot: Can technology help ex- pedite ADHD diagnosis? Chris Hollis, United Kingdom S hould non-stimulants be the first medication option for adult ADHD? Lessons from a nurse- led primary-care service John Ringhisen, USA A DHD in Sweden: Policy impacts on waiting lists Sven Bölte, Sweden
003
004
16
SCIENTIFIC PROGRAMME Thursday, 8 May 2025
HT-10 Hot Topic Session 17:00 – 18:30
HT-12 Hot Topic Session 17:00 – 18:30 ADHD in college-aged adults Chairs: Kevin M. Antshel, USA
South Hall 2A Hazard environmental exposure and the development of ADHD: Evidence from large population study Chairs: Takuya Saito, Japan, Li Yang, People‘s Republic of China 001 E nvironmental pollution exposure and ADHD symptoms: Progress in the Hokkaido study Takuya Saito, Japan
Club A
Jason Bantjes, South Africa
001
W hy focusing attention on ADHD is integral to supporting student mental health and academic success in South Africa Universities Jason Bantjes, South Africa ADHD in college students with sexual/gender minority identities Kevin M. Antshel, USA How effective and specific is extended time for college students? A randomized clinical trial Lui Martins Costa Malcon, Brazil Cognitive-behavioral intervention to treat executive dysfunction in college students with ADHD Sarah O’Neill, USA
002
P renatal opioid exposure and subsequent risk of ADHD: Nationwide birth cohort study in South Korea Jiseung Kang, Republic of Korea A n umbrella review of evidence on the as- sociation between environmental pollutant exposure and neurodevelopmental disorders Li Yang, People’s Republic of China
002
003
003
004
HT-11 Hot Topic Session 17:00 – 18:30
South Hall 2B Neurodiversity approach: Evidence for positive and strength focused aspects in ADHD Chairs: Martine Hoogman, The Netherlands Edmund Sonuga-Barke, United Kingdom 001 P ositive attitudes towards ADHD among diag- nosed individuals: Divergent influences across symptoms Nitzan Shahar, Israel
OC-01 Opening Ceremony 19:00 – 20:30
Congress Hall
Opening Ceremony Moderator: Michal Goetz, Czech Republic Welcome Address by the President of the World Federation of ADHD Stephen Faraone, USA Heinrich Hoffman Medal of the World Federation of ADHD Stephen Faraone, USA Experiences as an adult with ADHD raising a (now grown) adult with ADHD Katherine Ellison, USA Interview with Anita Thapar to get a child psychiatrist’s perspectives Katherine Ellison, USA Anita Thapar, United Kingdom At the end of the Opening Ceremony all participants are invited to join the Networking Reception in the exhibition area in in the Congress Hall Foyer on the 2 nd Floor.
002
Quantification of potential strengths in adults with ADHD Martine Hoogman, The Netherlands D istracted, hyperactive, and thriving: Factors supporting successful functioning in ADHD
003
across the adult lifespan Brandy Callahan, Canada
004
I would never give up my ADHD – high-func- tioning ADHD Myriam Bea, Germany
17
SCIENTIFIC PROGRAMME Friday, 9 May 2025
004
Exploring the microbiota-gut-brain axis in ADHD: Gut microbiome associations and therapeutic insights Debora Miranda, Brazil M. Romano-Silva, M. França, A. Alvim Soares Terrorized minds: Exploring the psychosocial impact of terrorism threats on adults with ADHD Rachel Shoham, Israel H. Dayan
PL-01 Plenary Session 08:30 – 10:00
Congress Hall
Translating ADHD research to clinical world Chairs: Stephen Faraone, USA Luis Augusto Rohde, Brazil 001
005
W hat clinicians need to know about ADHD genetics? Stephen Faraone, USA N on-pharmacological treatment for ADHD: What is almost there? Margaret Sibley, USA D igital solutions in the assessment and treat- ment of ADHD: What already helps clinicians? Manfred Döpfner, Germany
002
006
ADHD: From the bottom up Miguel Vizcaíno Da Silva, Spain
R. Blanco Fernández, R. Fernandez, A. Izquierdo Lapuente, P. Del Sol Calderón, A. Perez Balaguer, A. Rodriguez, M. Martin Garcia, O. Mendez Gonzalez, R. Albillos Perez, M. Garcia Moreno C ommon and different gut metagenomic and metabolic profiles linked to diverse ADHD presentations Xinyue Wang, People‘s Republic of China N. Wang, L. Yang
003
007
PL-02 Plenary Session 10:30 – 12:00
Congress Hall
ADHD and trauma across the lifespan Chairs: Mark Bellgrove, Australia Michal Goetz, Czech Republic 001
P-02 Guided Poster Tour 12:45 – 14:45 Genetics Chair: Ditte Demontis, Denmark 001
What should we make of the reported link between ADHD and maltreatment? Edmund Sonuga-Barke, United Kingdom Understanding ADHD in the context of genetic trauma predictors Ditte Demontis, Denmark Trauma recovery for ADHD with adverse childhood experiences - the work of trauma- focused psychotherapy in the perspective of adaptive information processing Jinsong Zhang, People’s Republic of China
Congress Hall Foyer 2B (2 nd Floor)
002
G enotype-phenotype association analysis of sustained attention in adult ADHD and in at- risk population Livia Balogh, Hungary A. Pulay, K. Vincze, Z. Hantos-Horváth, S. Bálint, T. Kilencz, V. Simon, Z. Nemoda, P. Czobor, I. Bitter, J. Réthelyi G enetic overlap between ADHD and migraine Pau Carabi Gassol, Spain M. Ribasés, J. Ramos-Quiroga, V. Macias, S. Alemany, C. Fadeuilhe, M. Corrales, V. Richarte, J. Cabana Domínguez, M. Soler Artigas M onogenic causes and pharmacogenetic thera- pies in ADHD Michele Ciliberto, Italy C. Modafferi, D. Segatori, R. Brugnoli, M. Mazza, G. Sani H igher socioeconomic status uncouples ADHD disease severity from polygenic risk burden in an ADHD population Carsten Drepper, Germany A. Chiocchetti, P. Poursafa, J. Geißler, A. Kaiser, T. Banaschewski, M. Romanos, E. Consortium Cell type-specific methylome-wide association studies of childhood ADHD symptoms Marieke Klein, The Netherlands M. Meijer, D. Caramaschi, S. Clark, B. Franke, W. Copeland, K. Aberg, E. Van Den Oord, P. Pace
003
002
P-01 Guided Poster Tour 12:45 – 14:45 Pathogenesis Chair: Edna Grünblatt, Switzerland 001
Congress Hall Foyer 2B (2 nd Floor)
003
The cerebellum in children and adolescents with ADHD Oliver Bilke-Hentsch, Switzerland I. Charrua, R. Yurchyshyn, D. Schutter ADHD and non-neurological medical comor- bidities: A narrative review Josh Kaplan, USA The role of current psychosocial stressors and post-trauma symptoms on the associa- tion between ADHD symptoms and executive functioning performance Michael Meinzer, USA L. Tufty, J. Harris, J. Soble
004
002
003
005
18
SCIENTIFIC PROGRAMME Friday, 9 May 2025
006
Investigating genetic variants in the Ras-MAPK pathway in ADHD and ASD using in vivo and in vitro approaches Anna Koutska, Czech Republic A. Vapenikova, P. Havlickova, T. Konikova, I. Kuta- Smatanova, M. Fencková E xploring copy number variants in a cohort of children affected by ADHD: Genetic insights and clinical perspectives Federica Mirabella, Italy V. Finocchiaro, M. Figura, O. Galesi, M. Elia, R. Barone, R. Rizzo M ulti-polygenic scores for externalizing be- havior among schoolchildren Uxue Zubizarreta Arruti, Spain M. Soler Artigas, R. Bosch, J. Cabana Domínguez, N. Llonga, J. Ramos-Quiroga, M. Pagerols, M. Casas, S. Alemany, M. Ribasés
007
An observational study on adults with ADHD in Italy Ilaria Gervasini, Italy S. Montanari, S. Beomonte Zobel, V. Pinzone, V. Piras, D. Segatori Prevalence of ADHD diagnosis in adults: A CPT database perspective Sam Goldstein, USA Exploring quality of life improvements in older adults with ADHD: A retrospective cohort study Maria Loureiro, Ireland S. Carty, K. Walker Association between maternal diabetes during pregnancy and neurodevelopmental outcomes in offspring: Results from individual partici- pant data meta-analysis in ten birth cohorts Rae-Chi Huang, Australia R. Pretorius, D. Avraam, M. Guxens, J. Julvez, J. Harris, J. Nader In utero exposure to ADHD medication and growth trajectories in the offspring from birth to 15 years: A Danish population-based cohort study Amalie Jensen, Denmark K. Marcussen, S. Möller, K. Madsen Do fathers with ADHD have an increased risk of perinatal loss and adverse perinatal out- comes? A population-based study Ammal Khan, Norway A. Engeland, B. Solberg, I. Brikell, K. Klungsøyr Socioeconomic and regional variations in ADHD medication prescribing in England Muhammad Umair Khan, United Kingdom S. Hasan The role of environmental and behavioral factors in early life associated with screen- ing positive for ADHD at 8 years of age: A longitudinal study in ‘The Norwegian Mother, Father and Child Study’ André Høberg, Norway R. Walters, J. Haavik, T. Zayats Prevalence of autism spectrum disorder in young people attending ADMiRE, Ireland’s first specialist paediatric ADHD service Jane McGrath, Ireland S. Killeen, M. Shipsey, S. Sexton, B. Cawley, S. Watters, S. Ryan, J. Behan, N. Tims, M. Grace Core symptoms and executive function char- acteristics of children with ADHD with and without motor development lag Ren Yuanchun, People‘s Republic of China L. Shengqi, K. Dongqing
008
007
009
008
010
P-03 Guided Poster Tour 12:45 – 14:45
011
Congress Hall Foyer 2B (2 nd Floor)
Epidemiology I Chair: Kathrine Bang Madsen, Denmark 001
Co-occurrence of sleep disorders with adult ADHD: Comparison with normal controls Dimitrios Adamis, Ireland J. Tiernan, N. Lagan, B. Gavin, F. McNicholas Screen time USAge patterns and associated factors among children with ADHD: A cross sectional analysis of multi device exposure
012
002
013
and parental regulation Ahmed Al Ansari, Bahrain
003
Increased risk of provisional premenstrual dysphoric disorder (PMDD) symptoms among females with ADHD Thomas Broughton, United Kingdom E. Lambert, J. Agnew-Blais R acial/Ethnic disparities in diagnosis of ADHD and comorbid disorders Jennifer Crosbie, Canada S. Shaikh, A. Dissanayake, A. Dupuis, P. Peter, A. Gajaria, P. Arnold, C. Burton, R. Schachar A DHD and cardiometabolic risk factors in adult type 2 diabetes: Baseline and longitudinal changes Zihan Dong, Sweden E. Du Rietz ADHD and comorbidities in childhood: Characterization, treatment and academic challenges Marta Ezequiel, Portugal R. Branco, R. Ribeiro Martins, J. Carreira, J. Matias, A. Queiroz, L. Ventosa, L. Rocha
014
004
015
005
016
006
19
SCIENTIFIC PROGRAMME Friday, 9 May 2025
011
Associations between ADHD symptoms and objectively measured physical activity across developmental stages among girls and boys: Findings from the Millennium Cohort Study Amandine Senequier, United Kingdom S. Iliodromiti, J. Agnew-Blais C omorbid problems of ADHD traits and other developmental traits in general university students: A pilot study Nana Shinoda, Japan N. Shinoda, H. Shinoda, E. Shimizu O verweight and obesity in school-aged chil- dren with ADHD: A retrospective study from Western China Jing Tan, People‘s Republic of China L. Chen, B. Peng The prevalence of ADHD in inpatients with a primary diagnosis of depression Svenja Wudy, Germany J. Huang, N. Mauche, C. Makiol, M. Strauß Investigating the effects of ethnic racial iden- tity on ADHD and comorbid psychopathology: Implications for racial-ethnic minority univer- sity students in the United States Michael Meinzer, USA C. Melendez Consistency of ADHD diagnosis during health- care transitions Alberto Rodríguez-Quiroga, Spain From focus to pressure: Exploring essential hypertension risk in Israeli children with ADHD M. Polukst, Israel E. Merzon, S. Ashkenazi, E. Grossman, A. Golan- Cohen, S. Vinker, A. Israel
P-04 Guided Poster Tour 12:45 – 14:45
Congress Hall Foyer 2B (2 nd Floor)
Epidemiology II Chair: Helen-Maria Vasiliadis, Canada 001
A DHD in psychiatry trainees: Patterns of diag- nosis, treatment and professional implications Raquel Medinas, Portugal M. Cândido, J. Azenha, J. Domingos, D. Sousa Prevalence, self-diagnosis and treatment of ADHD among medical trainees: A review of current evidence Raquel Medinas, Portugal M. Cândido, J. Azenha, J. Domingos, D. Sousa Association between ADHD and cardiometa- bolic risk profile in patients with acute myo- cardial infarction Honghui Yao, Sweden I. Brikell, H. Larsson, E. Rietz, C. Hartman, T. Jernberg, P. Andell, Z. Chang Professional perspectives on the management of adult ADHD in Italy Silvia Montanari, Italy I. Gervasini, S. Beomonte Zobel, V. Pinzone, V. Piras, D. Segatori Stimulant treatment for ADHD and risk of first and repeat juvenile criminal offending: A population-based cohort study Timothy Nielsen, USA R. Nanan, T. Butler, N. Nassar, A. Poulton A DHD and risk of cause-specific mortality: A population-based cohort study Timothy Nielsen, USA R. Nanan, T. Butler, N. Nassar, A. Poulton Global perspectives on ADHD treatment prac- tices in children and adolescents: A pilot study Özlem Özcan, Türkiye S. Uygun, E. Kurtuldu, D. Öztop Non-suicidal self-injury and ADHD in adults: A systematic review and meta-analysis Ambar Lyned Rodriguez-Araud, Puerto Rico M. Velez-Pastrana Adult ADHD: Associated medical conditions and related factors Luca Rolle, Italy C. Perotti, G. Di Salvo, G. Maina Seasonality and the impact of the COVID-19 pandemic on ADHD medication utilization in Poland Marcin Rzeszutek, Poland T. Wola ń czyk
012
002
013
003
014
015
004
005
016
017
006
007
P-05 Guided Poster Tour 12:45 – 14:45 Diagnosis, adults Chair: Wolfgang Retz, Germany 001
Congress Hall Foyer 2B (2 nd Floor)
008
Indicators of impulsivity in a routine clinical evaluation of adult ADHD Hui Dong, The Netherlands A. B. M. Fuermaier, J. Koerts, G. H. M. Pijnenborg, N. Guo, N. Scherbaum, B. Müller The clinical utility of QbMobile as a smart- phone application for the assessment of ADHD Urban Gustafsson, Sweden S. Larsson, N. Casals, R. Nolen, R. Sanyal, M. Hansen Temperament traits and ADHD subtypes in adults: Insights from latent profile analysis Henning Heinze, Germany C. Teuchert, J. Koerner, M. Daseking
009
002
010
003
20
SCIENTIFIC PROGRAMME Friday, 9 May 2025
004
Validity of an online assessment of ADHD among a real-world sample of adults seeking web-based behavioral healthcare Barry Herman, USA S. Faraone, A. Cutler, J. Newcorn, E. Lafrance, M. Ripper Lewis, C. Ruetsch AKCENT-ADHD: Unraveling clinical pathways and comorbidities of adult ADHD in Poland Rafał Jaeschke, Poland J. Sułkowska, M. Siwek, D. Dudek Machine learning for ADHD prediction using CPT on a smartphone application Simon Larsson, Sweden N. Casals, M. Hansen Impulsivity and ADHD: Conceptual background for a proposal of cardinal symptom Camila Martínez, Chile L. Flores Factor structure of the parent questionnaire of the Essen Interview on School Biographies (EIS-B) in the diagnosis of adult ADHD Bernhard W. Müller, Germany J. Weidner, P. Abdel-Hamid, D. Bauer, D. Brotte, D. Lyons, N. Rüdel, R. Schwierczok, P. Fürmaier, T. Zwarg, P. Scherbaum E valuating the feasibility and validity of Qbtest on a smartphone in participants assessed for ADHD Robert Nolen, USA H. Christiansen, U. Gustafsson, N. Casals, S. Larsson, R. Sanyal, M. Hansen N etworks and factors of symptom and per- formance validity in the clinical evaluation of adult ADHD Emily Raasch, Germany A. Fuermaier, J. Kneidinger, B. Albrecht, H. Christiansen Refining the diagnosis of ADHD in adulthood: Focus on sensitivity and specificity of assess- ment methods Laurence Rousselle, Belgium M. Noël Assessing the measurement invariance of the quick screen version of the Barkley Adult ADHD Rating Scale across sociodemographic characteristics Dustin Sarver, USA Enhancing accuracy in ADHD assessment: A critical examination of diagnosis reports Avital Tamsut, Israel T. Malinovitch, Y. Pollak, N. Saka
014
Meta-analysis: Continuous performance tasks as embedded performance validity indicators in adults assessed for ADHD Pinar Toptas, The Netherlands T. Dekkers, Y. Groen, G. Gaastra, D. Waard, A. Fuermaier Exploring the verbal behavior of ADHD in adults on social media through NLP-derived biomarkers and machine learning Daniel Wiechmann, Germany E. Kempa, E. Kerz, Y. Qiao
015
005
006
P-06 Guided Poster Tour 12:45 – 14:45
007
Congress Hall Foyer 2B (2 nd Floor)
Diagnosis, children and adolescents Chair: Tobias Banaschewski, Germany 001
Impact of online health education on ADHD screening results and parenting stress among school-aged children Jing Tan, People‘s Republic of China L. Chen, W. Yi, J. Shen, B. Peng, M. Gong, F. Li A semiologic representation the graphic or- ganisation of neurodevelopment disorders from chapter 6 of ICD-11 and DSM-V in chil- dren and adolescents
008
002
009
Vanessa Douet Vannucci, France M. Forestier, Y. Guigou, L. Pisella
003
Preliminary results of the EPIDIA4Kids study on brain functioning in children: Multidimensional ADHD-related symptomatology screening us-
010
ing multimodality biometry Vanessa Douet Vannucci, France Y. Guigou, L. Pisella, P. Staccini
004
D o difficulties with concentration, hyperactiv- ity, and impulsive behaviour always lead to a diagnosis of ADHD? Virginie Fouarge, Belgium X. Colpaert, E. Cloet Development and preliminary validation of a brief questionnaire focused on assessing and understanding disruptive behavior, reactivity, and emotion/mood dysregulation in youth (AUDREY) Paulo Graziano, USA M. Hernandez, M. Curzon, M. Johansson, E. Goldhagen, L. Reinoso iPad-based tool for assessing executive func- tion and processing speed in adolescents with ADHD Anne Gulsrud, Norway I. Haugen, A. Dyresen, J. Stubberud, K. W. Fjermestad, L. Tjelta Westlye, D. Alnæs, M. Glenne Øie
011
005
012
013
006
21
SCIENTIFIC PROGRAMME Friday, 9 May 2025
007
Translation and cultural adaptation of the vanderbilt ADHD diagnostic rating scale into Georgian: A first step toward enhanced ADHD diagnosis in Georgia Ana Makharashvili, Georgia R. Polimanti T he Child Health Integrated Response Pathway (CHIRP) and implementing an objective psy- chometric tool: QbCheck. improving ADHD pathway efficiency in the Bay of Plenty, New Zealand Sarah Moll, New Zealand K. Blair, H. Barrow, C. Malone, C. Frampton, A. Theron A systematic review of ecological momentary assessment studies on ADHD Alexandra Nistor, Romania C. Poetar The utility of the QbTest as a diagnostic aid in a specialist ADHD service: A retrospective chart review Declan Quinn, Ireland J. McGrath, R. Whelan, S. O’Leary, M. Shipsey, S. Ryan, M. Groom Examining the ability of the hyperactivity/inat- tention subscale of the self-reported strengths and difficulties questionnaire to identify ado- lescents with a recorded ADHD diagnosis Abbey Rowe, United Kingdom K. Langley, G. Moore, A. Thapar, H. Lohakare, A. John, A. Marchant ADHD identification based on video game performance David Delgado-Gomez, Spain L. Caselles-Pina, A. Quesada-López, E. Garzón- Hernández
002
Understanding the mechanistic links between neurodevelopmental traits and internalising problems: The mediating roles of intolerance of uncertainty and negative problem orienta- tion Luca Hargitai, United Kingdom L. Waldren, R. Robinson, F. Leung, L. Livingston, P. Shah Analyzing the association between social anxiety and ADHD symptoms: A predictive and correlational study Ben Kneubuehler, Switzerland Exploring sleep in adult ADHD: Polysomno- graphic and subjective findings and their links to symptom severity and psychiatric comor- bidities Solveig Menrad, Germany E. Künstler, T. Schultze, H. Schneider, S. Rupprecht Perceived stress, self-efficacy and mindful- ness mediate the relationship between ADHD symptoms and anxiety/depression in adult ADHD Shan Qu, People‘s Republic of China S. Zhang, X. Shi Maltreated ecophenotype in ADHD: Evidence for worse comorbid, but not ADHD symptoms or interpersonal problems, when considering confounding by mental health problems Kristóf Ágrez, Hungary N. Bunford Irritability works as a mediator between de- pression and hyperactivity in children with ADHD Jamile Noele De Andrade, Brazil D. De Paula Da Silva, M. Maria, M. Romano-Silva, D. Marques De Miranda Predicting long-term treatment outcomes in youth with anxiety disorders: The role of externalising symptoms Agnete Dyresen, Norway K. Westlye Fjermestad, A. Kodal, M. Posserud, M. Glenne Øie, G. Henningsen Wergeland Comorbid ADHD and disruptive behavior dis- orders: The role of executive functioning Margaret Johansson, USA M. Hernandez, M. Curzon, E. Goldhagen, L. Reinoso, A. Dick, P. Graziano Clinical and cognitive mediators underlying subsequent depression in individuals with ADHD: A developmental approach Egl ė Padaigait ė -Gulbinien ė , United Kingdom G. Hammerton, J. Heron, O. Eyre, G. Michelini, A. Wilson-Newman, C. Garavini, T. Eley, A. Thapar, L. Riglin
008
003
004
009
011
005
012
006
007
013
008
P-07 Guided Poster Tour 12:45 – 14:45
Congress Hall Foyer 2B (2 nd Floor)
Comorbidity Chair: Susan Young, United Kingdom 001
009
ADHD symptoms, cyclothymic temperament, and their associated impairments across adult- hood: A cross-sectional study Andre Høberg, Norway A. Austgulen, L. Østrådt-Jennings, A. J. Lundervold, B. Solberg, T. A. Hegvik, J. Haavik
010
22
SCIENTIFIC PROGRAMME Friday, 9 May 2025
011
A n audit of psychiatric comorbidity in children with ADHD within a learning disability service Shashi Kiran, United Kingdom M. Laxton-Kane, G. Whetton, M. Alexander
003
Longitudinal perspective on adolescent e-cig- arette use: The role of child ADHD symptoms and parenting characteristics Fabiola Gonzalez-Mendez, Puerto Rico M. Velez-Pastrana, A. Matos-Moreno, R. Partovi, K. Roche P atterns of methylphenidate misuse and abuse in patients with dual diagnosis Pietro Domenico Gramuglia, Italy S. Chiappini Emotion dysregulation as a core transdiag- nostic symptom in co-occurring substance use
P-08 Guided Poster Tour 12:45 – 14:45 Autism spectrum disorders Chair: Guilherme Polanczyk, Brazil 002
004
Congress Hall Foyer 2B (2 nd Floor)
005
The relationship among sensory processing, ADHD symptoms, autistic traits and opposi- tional defiant disorder manifestation in chil- dren with ADHD: The exploration based on network analyses Yuan Gao, People‘s Republic of China J. Li, W. Wang, H. Li, Q. Qian, Y. Wang, L. Liu Towards a better understanding of adverse life experiences in ADHD and autism Olujolagbe Layinka, United Kingdom P. Shah, L. Livingston The effect of autistic traits on creativity fea- tures in adults with ADHD Ningning Liu, People‘s Republic of China Z. Mu, A. Bau, J. Liu, X. Wang, J. Qiu, J. Xu, H. Li, Q. Qian, L. Liu Safety of rare sugar d-allulose in patients with autism sprectrum disorder with or without ADHD: A randomized double-blind placebo- controlled crossover trial Koyuru Kurane, Japan M. Yukifumi, M. Mieno, Y. Iwasaki, T. Yada
disorder and ADHD: A review Lisa Horstman, The Netherlands M. Hoogman, A. Schellekens
006
The chaos of adolescence: ADHD and use of psychoactive substances Zrinka Ć avar, Croatia A. Radic, L. Sabljic, S. Salamon Preventing relapse and maintaining remission in those with co-occurring SUD and ADHD Scott Keel, USA A DHD severity in adults: Linking stress, sleep, hormonal factors, and subsequent behavioural and substance-based addictions Asad Raffi, United Kingdom U. Yasin, I. Naeem S ubstance use disorders in adults with ADHD presenting with externalizing and internal- izing comorbidities Mario Louza, Brazil C. Salgado, E. Vitola, M. Tavares, D. Amado, B. Silva, G. Andrade, D. Rovaris, E. Grevet, C. Bau
003
007
004
008
006
009
P-09 Guided Poster Tour 12:45 – 14:45 Substance use disorders Chair: Brooke Molina, USA 001
P-10 Guided Poster Tour 12:45 – 14:45 Electrophysiology Chair: Maria Strauß, Germany 001
Congress Hall Foyer 2B (2 nd Floor)
Congress Hall Foyer 2B (2 nd Floor)
Increased risk for ADHD treatment discontinu- ation in adolescents and young adults with ADHD and comorbid substance use disorder: A register-based study Andrea Johansson Capusan, Sweden L. Zhang, Z. Chang A dvancing ADHD and substance use disorder management: A collaborative, evidence-based approach Samuel Chang, Canada A. Bickle, A. Davis, E. Climie, G. Ahmed, J. Picado, L. Amirali, L. Nix, M. Toplak, M. Gignac, S. Espinet
The attentional processing in adults with ADHD on frustration task: Based on event- related potential study Shoou-Lian Hwang-Gu, Taiwan Y. Chen Characteristics of handwriting skills sEMG- based in children with ADHD students of dif- ferent gender Ren Yuanchun, People‘s Republic of China B. Xiaoyu
002
002
23
Page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 Page 10 Page 11 Page 12 Page 13 Page 14 Page 15 Page 16 Page 17 Page 18 Page 19 Page 20 Page 21 Page 22 Page 23 Page 24 Page 25 Page 26 Page 27 Page 28 Page 29 Page 30 Page 31 Page 32 Page 33 Page 34 Page 35 Page 36 Page 37 Page 38 Page 39 Page 40 Page 41 Page 42 Page 43 Page 44 Page 45 Page 46 Page 47 Page 48 Page 49 Page 50 Page 51 Page 52 Page 53 Page 54 Page 55 Page 56 Page 57 Page 58 Page 59 Page 60 Page 61 Page 62 Page 63 Page 64 Page 65 Page 66 Page 67 Page 68Made with FlippingBook Digital Publishing Software